We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-14.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$203M
AUM Growth
-$48.1M
Cap. Flow
-$4.46M
Cap. Flow %
-2.19%
Top 10 Hldgs %
43.02%
Holding
56
New
10
Increased
13
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$3.87M
2
INDP icon
Indaptus Therapeutics
INDP
+$3.69M
3
XOMA
Xoma
XOMA
+$3.63M
4
BPMC
Blueprint Medicines
BPMC
+$3.6M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$3.28M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$7.91M
2
MDXG icon
MiMedx Group
MDXG
+$7.15M
3
CMRX
Chimerix, Inc.
CMRX
+$6.42M
4
CEMP
Cempra, Inc.
CEMP
+$4.83M
5
MGNX icon
MacroGenics
MGNX
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 89.51%
2 Miscellaneous 10.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
26
DELISTED
Blueprint Medicines
BPMC
$2.77M 1.37%
+130,000
New +$3.6M
ADMS
27
DELISTED
Adamas Pharmaceuticals
ADMS
$2.77M 1.37%
165,700
+15,700
+10% +$357K
MNTA
28
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.63M 1.29%
+160,000
New +$3.28M
TGTX icon
29
TG Therapeutics
TGTX
$8.53B
$2.62M 1.29%
+260,000
New +$3.87M
AGRX
30
DELISTED
Agile Therapeutics
AGRX
$2.6M 1.28%
193
+165
+589% +$2.93M
AVGR
31
DELISTED
Avinger, Inc. Common Stock
AVGR
$2.57M 1.27%
1
-1
-50% -$1.73M
ALPN
32
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.27M 1.12%
+43,800
New +$2.88M
XOMA
33
DELISTED
Xoma
XOMA
$2.22M 1.09%
147,500
+115,000
+354% +$3.63M
FOMX
34
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.09M 1.03%
285,000
+200,000
+235% +$2.04M
TENX icon
35
Tenax Therapeutics
TENX
$82M
$1.91M 0.94%
20
– –
AXDX
36
DELISTED
Accelerate Diagnostics
AXDX
$1.54M 0.76%
9,500
-560
-6% -$121K
CYTO
37
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.26M 0.62%
4
– –
XENE icon
38
Xenon Pharmaceuticals
XENE
$6B
$1.25M 0.62%
+151,300
New +$1.5M
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$846K 0.42%
+20,000
New +$1.23M
EVOK
40
DELISTED
Evoke Pharma
EVOK
$757K 0.37%
1,806
+7
+0.4% +$4.4K
INNL
41
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$695K 0.34%
55,543
-45,657
-45% -$629K
CELGZ
42
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$547K 0.27%
340,000
-116,492
-26% -$225K
ALDR
43
DELISTED
Alder Biopharmaceuticals
ALDR
$527K 0.26%
+16,100
New +$684K
CYNA
44
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$469K 0.23%
+29,000
New +$471K
BLRX
45
BioLineRX
BLRX
$12.1M
$383K 0.19%
417
– –
MDXG icon
46
MiMedx Group
MDXG
$657M
– –
-617,000
Closed -$7.15M
MGNX icon
47
MacroGenics
MGNX
$260M
– –
-90,000
Closed -$3.42M
CLVS
48
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-90,000
Closed -$7.91M
TTPH
49
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-3,250
Closed -$3.08M
DERM
50
DELISTED
Dermira, Inc.
DERM
– –
-18,800
Closed -$330K
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2015 Portfolio in Review

As of Q3 2015, Opaleye Management held 56 positions worth $203M, down 19% from $251M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management's Q3 2015 filing shows 10 new, 13 increased, 12 reduced and 7 closed positions. Its largest new stake was TG Therapeutics: 260,000 shares worth $2.62M. The largest sale was Clovis Oncology, Inc., an estimated $7.91M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 94% a quarter earlier, followed by Miscellaneous.

  • Opaleye Management's largest Q3 2015 buy was TG Therapeutics: 260,000 shares worth $2.62M.
  • Opaleye Management added most to Xoma in Q3 2015, an estimated $3.63M increase.
  • Opaleye Management's biggest Q3 2015 reduction was Chimerix, Inc., cutting an estimated $6.42M.
  • Opaleye Management fully exited Clovis Oncology, Inc. in Q3 2015, selling an estimated $7.91M.
  • Opaleye Management's ten largest holdings make up 43% of its $203M portfolio in Q3 2015.
  • Opaleye Management opened 10 new positions and closed 7 in Q3 2015.
  • Opaleye Management's portfolio value fell 19% quarter-over-quarter to $203M.

Based on Opaleye Management's 13F filing for Q3 2015, filed 13 Nov 2015.